Skip to main content
logo
AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
210.40
+2.48 (1.19%)
At close: Aug 29, 2025, 4:00 PM
210.40
0.00 (0.00%)
After-hours: Aug 29, 2025, 6:30 PM EDT

AbbVie Revenue by Segment

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Immunology
28.24B27.58B26.68B26.34B26.08B25.92B26.14B27.11B
Immunology Growth
8.27%6.39%2.09%-2.83%-6.78%-8.64%-9.64%-2.30%
Neuroscience
9.84B9.32B9.00B8.58B8.26B7.99B7.72B7.33B-------
Neuroscience Growth
19.03%16.64%16.61%17.06%18.70%18.59%18.21%13.30%-------
Hematologic Oncology
6.69B6.65B6.56B6.37B6.20B6.04B5.92B6.04B
Hematologic Oncology Growth
7.89%9.98%10.82%5.57%0.37%-4.81%-10.07%-11.47%
Aesthetics
4.92B5.03B5.18B5.25B5.25B5.24B5.29B5.21B-------
Aesthetics Growth
-6.31%-4.08%-2.23%0.75%-0.44%-0.30%-0.73%-4.46%-------
Other Products
3.63B3.56B3.65B3.70B3.79B3.78B3.81B3.82B
Other Products Growth
-4.24%-5.85%-4.15%-3.14%-1.51%-2.50%-1.25%-11.01%
HCV
---------------------2.68B2.93B3.16B3.32B
Eye Care
2.19B2.21B2.24B2.18B2.26B2.35B2.42B2.42B-------
Eye Care Growth
-3.10%-5.76%-7.16%-9.88%-7.26%-7.60%-10.59%-21.20%-------
Women's Health
--------------796.00M829.00M866.00M822.00M-------

Revenue by Geography

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
United States
44.62B43.97B43.03B42.41B42.11B41.72B41.88B42.97B
United States Growth
5.97%5.38%2.74%-1.30%-4.03%-6.38%-8.38%-4.94%
International
13.71B13.40B13.31B13.13B12.89B12.68B12.44B12.17B
International Growth
6.31%5.68%7.00%7.85%6.12%4.15%0.76%-3.55%

Operating Expense Breakdown

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018
Selling, General, and Administrative
14.61B14.73B14.75B14.09B13.26B13.15B12.87B13.10B
Selling, General, and Administrative Growth
10.18%12.03%14.61%7.59%1.76%-13.34%-15.65%-13.29%
Research and Development
13.10B12.92B12.79B7.94B7.54B7.32B7.68B7.54B
Research and Development Growth
73.84%76.44%66.66%5.39%1.45%0.23%17.90%15.14%
Acquired In-Process R&D
2.73B2.84B2.76B1.47B1.45B792.00M778.00M739.00M---
Acquired In-Process R&D Growth
88.20%258.71%254.37%98.24%103.23%12.82%11.62%-13.97%---
Other Expenses
-62.00M--352.00M------358.00M-22.00M-----------
Other Expenses Growth
---------------------
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.